• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Senseonics Holdings Inc. (Amendment)

    2/11/22 8:15:22 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care
    Get the next $SENS alert in real time by email
    SC 13G/A 1 p22-0811sc13ga.htm SENSEONICS HOLDINGS, INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G/A
     
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. 1)*
     

    Senseonics Holdings, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    81727U105

    (CUSIP Number)
     

    December 31, 2021

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 6 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 81727U10513G/APage 2 of 6 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Highbridge Capital Management, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    12,594,473 shares of Common Stock issuable upon conversion of convertible notes

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    12,594,473 shares of Common Stock issuable upon conversion of convertible notes

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    12,594,473 shares of Common Stock issuable upon conversion of convertible notes

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.75%

    12

    TYPE OF REPORTING PERSON

    IA, OO

             

     

     

    CUSIP No. 81727U10513G/APage 3 of 6 Pages

     

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Senseonics Holdings, Inc. (the “Company”).

     

    Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company’s principal executive offices are located at 20451 Seneca Meadows Parkway, Germantown, MD 20876-7005.

     

    Item 2(a). NAME OF PERSON FILING:
    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    Item 2(c). CITIZENSHIP:
       
      This statement is filed by:

     

      (i)

    Highbridge Capital Management, LLC

    277 Park Avenue, 23rd Floor

    New York, New York 10172

    Citizenship: State of Delaware

     

      The foregoing person is hereinafter sometimes referred to as the “Reporting Person.”
       
    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.001 per share (the “Common Stock”).

     

    Item 2(e). CUSIP NUMBER:
       
      81727U105
       
    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act,
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act,
      (c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act,
      (d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940,
      (e) ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E),
      (f) ¨ Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F),

     

    CUSIP No. 81727U10513G/APage 4 of 6 Pages

     

      (g) ¨ Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),
      (h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act,
      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J),
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:__________________________

     

    Item 4. OWNERSHIP.
       
      (a) Amount beneficially owned:
       
      As of December 31, 2021, Highbridge Capital Management, LLC, as the trading manager of Highbridge Tactical Credit Master Fund, L.P. and Highbridge Convertible Dislocation Fund, L.P. (collectively, the "Highbridge Funds"), may be deemed to be the beneficial owner of the 12,594,473 shares of Common Stock issuable upon conversion of convertible notes held by the Highbridge Funds.
       
      (b) Percent of class:
       
      The percentages used herein and in the rest of this Schedule 13G/A are calculated based upon 445,982,671 shares of Common Stock reported to be outstanding as of November 5, 2021, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021 filed with the Securities and Exchange Commission on November 9, 2021.
       
      The foregoing should not be construed in and of itself as an admission by the Reporting Person as to beneficial ownership of the shares of Common Stock issuable upon conversion of the convertible notes held by the Highbridge Funds.
       
      (c) Number of shares as to which such person has:
       
      (i) Sole power to vote or to direct the vote
       
      0

      

      (ii) Shared power to vote or to direct the vote
       
      See Item 4(a)
       
      (iii) Sole power to dispose or to direct the disposition of
       
      0

     

    CUSIP No. 81727U10513G/APage 5 of 6 Pages

     

       
     

    (iv)       Shared power to dispose or to direct

    the disposition of

       
      See Item 4(a)

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:x

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      See Item 4.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.
       
      The Reporting Person hereby makes the following certification:

     

      By signing below the Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 81727U10513G/APage 6 of 6 Pages

    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATED: February 11, 2022

     

    HIGHBRIDGE CAPITAL MANAGEMENT, LLC
         
         
    By: /s/ Kirk Rule  
    Name: Kirk Rule  
    Title: Executive Director  
         

     

     

    Get the next $SENS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SENS

    DatePrice TargetRatingAnalyst
    10/21/2025$9.00Hold
    Stifel
    8/27/2025$1.50Overweight
    Barclays
    7/15/2025$1.25Buy
    TD Cowen
    6/2/2025$1.10Buy
    H.C. Wainwright
    4/10/2025$2.00Outperform
    Mizuho
    7/19/2023$0.50Underperform
    Jefferies
    8/19/2021$6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SENS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Roeder Douglas A bought $126,134 worth of shares (22,686 units at $5.56), increasing direct ownership by 19% to 144,635 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    5/13/26 4:15:05 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Director Roeder Douglas A bought $100,275 worth of shares (17,500 units at $5.73), increasing direct ownership by 17% to 119,731 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    3/16/26 10:44:45 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    President and CEO Goodnow Timothy T bought $99,733 worth of shares (17,225 units at $5.79), increasing direct ownership by 3% to 651,243 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    3/16/26 10:44:00 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Senseonics Highlights Analyst Event and Oral Presentation of Eversense 365 Real-World Evidence at ADA 2026

    GERMANTOWN, Md., June 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today highlights two key company events during the 86th Scientific Sessions of the American Diabetes Association (ADA), taking place June 5-8 in New Orleans, Louisiana. Senseonics will be hosting an analyst event to discuss the Eversense 365 platform, as well as an oral presentation on the ADA program discussing real world evidence of the world's first and only one year CGM system. Analyst Event DetailsSenseonics

    6/1/26 8:00:00 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Senseonics Holdings, Inc. Reports First Quarter 2026 Financial Results

    Generated Q1 revenue of $11.7 million, an increase of 87% year-over-year Expect full-year revenue in the range of $60M - $64M (previously $58M to $62M) Strong strategic and commercial progress, including the launch of Eversense® 365 in Europe Raised $100M+ in equity and debt financing to support commercial strategy and pipeline GERMANTOWN, MD., May 07, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced first quarter 2026 financial results and provided a business update

    5/7/26 4:01:00 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Senseonics Announces Closing of $92 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

    GERMANTOWN, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on the design, development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the closing of its previously announced underwritten public offering of $92 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants. Senseonics sold 10,400,000 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 2,400,000 additional shares of common stock, and 8,000,000 pre-funded warrants. The shares of c

    5/4/26 4:01:00 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel resumed coverage on Senseonics with a new price target

    Stifel resumed coverage of Senseonics with a rating of Hold and set a new price target of $9.00

    10/21/25 7:22:14 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Barclays initiated coverage on Senseonics with a new price target

    Barclays initiated coverage of Senseonics with a rating of Overweight and set a new price target of $1.50

    8/27/25 8:26:33 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    TD Cowen initiated coverage on Senseonics with a new price target

    TD Cowen initiated coverage of Senseonics with a rating of Buy and set a new price target of $1.25

    7/15/25 8:44:36 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    SEC Filings

    View All

    SEC Form SD filed by Senseonics Holdings Inc.

    SD - Senseonics Holdings, Inc. (0001616543) (Filer)

    6/1/26 5:07:59 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Senseonics Holdings Inc.

    S-8 - Senseonics Holdings, Inc. (0001616543) (Filer)

    5/20/26 4:51:58 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Senseonics Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Senseonics Holdings, Inc. (0001616543) (Filer)

    5/20/26 4:29:06 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Kaufman Francine was granted 63,177 shares, increasing direct ownership by 54% to 181,067 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    5/21/26 5:42:42 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    GC & Corp. Development Advisor Horton Kenneth L was granted 157,943 shares, increasing direct ownership by 115% to 295,057 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    5/21/26 5:41:33 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Chief Operating Officer Jain Mukul was granted 270,759 shares, increasing direct ownership by 110% to 517,057 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    5/21/26 5:40:28 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Leadership Updates

    Live Leadership Updates

    View All

    Vistagen Appoints Nick Tressler as Chief Financial Officer

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po

    12/1/25 8:30:00 AM ET
    $AZN
    $SENS
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $SENS
    Financials

    Live finance-specific insights

    View All

    Senseonics Holdings, Inc. Schedules First Quarter 2026 Earnings Release and Conference Call for May 7, 2026 at 4:30 P.M. Eastern Time

    GERMANTOWN, Md., May 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2026 financial results after market close on Thursday, May 7, 2026. Management will hold a conference call to review the Company's first quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseon

    5/1/26 9:10:31 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year Received CE Mark approval for commercialization of Eversense 365 in Europe Launched first Eversense 365 AID system integration, with twiist in the US GERMANTOWN, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced fourth quarter 2025 financial results and provided a business update. Recent Highlights & Accomplishments Generated fourth quarter 2025 revenue of $14.3 million, an increase

    3/2/26 4:01:00 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Senseonics Announces Preliminary Unaudited Revenue for Fourth Quarter 2025 and Provides Business Update

    Preliminary unaudited revenue expected to be approximately $14.2 million for Q4 2025, an increase of 71% year-over-year Introduced 2026 revenue guidance of $58-$62 million Expects to report fourth quarter and full year 2025 financial results on March 2, 2026 GERMANTOWN, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced preliminary revenue for the fourth quarter of 2025 and provided a general business update. Recent Highlights & Accomplishments Generated preliminary unaudite

    1/12/26 8:00:00 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Senseonics Holdings Inc. (Amendment)

    SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)

    2/13/24 5:13:59 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Senseonics Holdings Inc. (Amendment)

    SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)

    7/7/23 4:35:55 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Senseonics Holdings Inc.

    SC 13G - Senseonics Holdings, Inc. (0001616543) (Subject)

    4/10/23 5:10:45 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care